Early results from the phase three trials will determine the effectiveness of the Oxford-AstraZeneca vaccine.
Separately, Pfizer-BioNTech and Moderna have already published preliminary data from their respective phase three trials, and both have proven to be highly protective against Covid infection.
Drugmakers and research centers are scrambling to deliver a vaccine to help bring an end to the coronavirus pandemic that has claimed over 1.3 million lives.
“We are not in a rush and it is not a competition with the other developers. What we are trying to do is to make sure that we have very high-quality data, working with our partners in the other countries, and to be able to present the results of the trial,” Pollard said during an online media briefing.
“As far as the timing of that, it is going to be when it is ready.”
The next step, Pollard explained, would be to provide regulators with all of the data and await a decision on licensing.
“If that process happens in due haste and speed that is appropriate in the pandemic, then it is possible that things could line up so there is not very much difference in timing between the various different vaccines,” he said.
“I think in order to understand exactly which one will happen when, we need to have a lot more information that I don’t have about when, for example, Pfizer or Moderna will deliver their first doses.”
“It’s uncertain from where I see things, it will be other people who need to answer that,” Pollard said.